Symbiotec Pharmalab Schedules Q1FY27 Earnings Call for 22nd Sep'26
Symbiotec Pharmalab Ltd 路 Intimation 路 22 Sept 2026, 10:00 am
Symbiotec Pharmalab Schedules Q1FY27 Earnings Call for 22nd Sep'26 Symbiotec Pharmalab Limited will host its Q1FY27 earnings conference call on 22nd Sep'26 at 10:00 AM IST to discuss financial performance and business updates for the quarter ended 30th Jun'26. Organized by JM Financial Institutional Securities Limited, the call will feature key management participants, including Promoter & CMD Anil Satwani and Chief Financial Officer Raghavender Ramachandran. Universal dial-in access is available via +91 22 6280 1366 and +91 22 7115 8267, alongside international toll-free numbers for the USA, UK, Singapore, and Hong Kong.
Original exchange filing (PDF)
More announcements from Symbiotec Pharmalab Ltd
- Intimation regarding change in Corporate Identification Number (CIN) and Listing Status of the Company. 路 17 Nov 2026
- Transcript of the Earnings conference call for the Analysts and Investors for the Quarter and Half year ended 路 12 Nov 2026
- Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time .... 路 12 Nov 2026
- Pursuant to Part A of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Audio recording of Conference Call for Analysts and Investors held on November .... 路 06 Nov 2026
- Symbiotec Signs 10 Year take or Pay Agreement to Manufacture Fermentation based alternative protein for EU Innovator 路 06 Nov 2026
- The Monitoring Agency report issued by the CARE Edge Ratings, Monitoring Agency, appointed by the Company for the utilisation and application of funds raised through the IPO of the Company .... 路 06 Nov 2026
- The Investor release being issued by the company, for the quarter and half year ended September 30, 2026 路 06 Nov 2026
- Pursuant to regulations 30 of the SEBI Listing Regulations, Investor Presentation on the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2026. 路 06 Nov 2026
